US 12,496,303 B2 · Conditioning agents for use in allogeneic hematopoietic stem cell transplantation

Abstract

Among the various aspects of the present disclosure is the provision of conditioning agents for use in allogeneic hematopoietic stem cell transplantation. An aspect of the present disclosure provides for a method of treating a subject or inhibiting alloreactivity in the host-versus-graft direction comprising administering a combination of conditioning agents comprising an anti-body-drug conjugate (ADC) and a JAK1/JAK2 inhibitor for use in allogeneic hematopoietic stem cell transplantation in an amount sufficient to permit engraftment of allogeneic bone marrow. In some embodiments, the ADC is selected from CD45-SAP, cKit-SAP, CD117-Amanitin, and CD45-PBD. In some embodiments, the JAK1/JAK2 inhibitor is selected from baricitinib and ruxolitinib. In some embodiments, the method further comprises administering a cancer therapeutic.

Claims21

Dependent claims

A method of inhibiting alloreactivity in a subject prior to an allogeneic hematopoietic stem cell transplant (allo-HSCT), the method comprising:

administering, prior to the allo-HSCT, a hematopoietic stem cell (HSC)-depleting antibody-drug conjugate (ADC) in an amount effective to deplete hematopoietic stem cells (HSCs) in the subject and to create space for transplanted donor HSCs, wherein the HSC-depleting ADC targets CD45;
administering, prior to the allo-HSCT, an amount of a JAK1/JAK2 inhibitor in an amount effective to permit engraftment of allogeneic bone marrow;
and
administering the allo-HSCT to the subject,
wherein the subject does not receive chemotherapy, irradiation, or pan T cell depletion (pan-TCD) prior to receiving the allo-HSCT.

2 more elements

Dependencies are inferred from the claim text.

Conditioning agents for use in allogeneic hematopoietic stem cell transplantation

Life of this patent

Conditioning agents for use in allogeneic hematopoietic stem cell transplantation

Life of this patent

Abstract

Claims21